Common Sense Oncology will be at this year's American Society of Clinical Oncology (ASCO) annual meeting in Chicago! Join us to explore what truly matters to cancer patients, including the balance between science, commercial interests, and the hype around oncology advances. We'll dive into crucial topics such as new drugs, pharmaceutical companies, patient priorities, and the significance of value-based care. Looking forward to insightful discussions with Bishal Gyawali , Queen's University , Tim Hanna Richard Sullivan Susie Stanway,Nazik Hammad,Brian Shkabari,Fidel Rubagumya ,M.D, MMed, MPH, PhD (c) , VERNA VANDERPUYE Dr. Fabio Ynoe de Moraes See you there! #ASCO #Oncology #CancerCare #Science #PatientPriorities #ChicagoMeeting

Teva Pharmaceuticals and mAbxience are expanding their strategic partnership to bring an 𝐚𝐧𝐭𝐢-𝐏𝐃-𝟏 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 to the global market. This new collaboration highlights our commitment to developing cost-effective cancer treatments and improving healthcare outcomes for patients around the world. With Teva’s regulatory and commercial strength and mAbxience’s cutting-edge production, this partnership aims to make 𝐡𝐢𝐠𝐡-𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞, 𝐭𝐡𝐞 𝐔.𝐒., 𝐚𝐧𝐝 𝐛𝐞𝐲𝐨𝐧𝐝. Together, we are 𝐚𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐜𝐚𝐫𝐞 and making a real impact. Stay tuned for more updates on our journey to bring innovative treatments to patients! 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐨𝐫𝐲 𝐡𝐞𝐫𝐞: https://lnkd.in/g-CNfJZx #TevaPharma #Biosimilars #CancerTreatment #mAbxience #HealthcareInnovation #OncologyCare #BiotechPartnerships #PatientFirst #OncologyBiosimilars #GlobalHealth #PharmaInnovation #PD1Inhibitors #BiosimilarDevelopment #MedicalBreakthroughs

📢 Explore the future of oncology with our latest white paper 📰 , delving into groundbreaking research, innovative therapies, and the evolving landscape of cancer treatment. To gain valuable insights and stay ahead in the rapidly advancing field of oncology, visit our website🌐https://lnkd.in/gmGzA86H for more information. #Oncology #CancerResearch #InnovationInHealthcare #WhitePaper #GU24 #asco #conference #pharmanews #pharmaceutical #healthcare #pharmaceuticalindustry #ASCOGU24 #MedicalConference

ASCO GU 2024 Highlights - clear progress in the genitourinary cancer space but key questions remain. Read more from our experts or DM for further details Non-metastatic prostate cancer: - With active surveillance being recommended for low-risk PCa, are there opportunities for any systemic treatment? - Can NHTs secure approvals for localized disease? Metastatic prostate cancer: - While triplet regimens (NHT + chemo + ADT) are approved in mHSPC, are patients willing to tolerate chemo-toxicities? - Can anti-PSMA RLTs expand to earlier lines? Even if approved, will they be widely accessible? - Can other PSMA-targeting modalities (ADC, bsAb & CARTs) replicate the efficacy of RLTs? - What is the exact role of the current PARPi? - Is there any hope for anti-PD-(L)1s, following the failure of several large Ph 3 trials? What are the prospects of CONTACT-02 (anti-PD-L1 +TKI)?  Bladder cancer:  NMIBC  - With the increasing use of bladder-preserving treatments, what are the future options available before and after BCG treatments? - Can localized intravesical therapies replace BCG? MIBC: - What is the role of ICP (immune checkpoint) inhibitors in a perioperative MIBC setting? mUC - What is the role of biomarker-targeted therapies and how will they be sequenced vs. PD(L)1 in light of recent FDA actions? RCC - Role of SC vs. IV PD-1s? Will higher ADA impact the higher convenience offered by SC? - While recent PD-1 data showed OS benefit adjuvant ccRCC, why did previous PD-(L)1 trials fail?

With oncology trial starts at historically high levels in 2022, the volume of innovation we’re seeing in cancer care is inspiring excitement in experts across the globe. In this article for European Biopharmaceutical Review, IQVIA’s Sari Heitner Enschede, Jose Luis Garcia, and Matthew Simmons take a deep-dive into the implications of oncology practice-shifting advancements on patient care. Read now. Pages 60-63: https://bit.ly/3UiCGjy #oncology #clinicaltrials

How can pharma sponsors successfully navigate the critically important early phase development of their oncology therapies? With 2023’s new FDA Guidance for Dosage Optimization in Oncology Treatment (known as Project Optimus) and the increasingly complex and varied oncology therapies landscape, smart trial design is essential to finding success. Download the free article now: https://ow.ly/vJcg50QXV4m #PharmaSponsors #DosageOptimization #OncologyTherapies

Cancer research is increasing with the sole goal of providing tailored therapies to the patients; every journey is different. “A priority for everyone… as it relates to improving equitable treatment access and making sure patients’ quality of life is considered alongside drug efficacy”. Two FDA initiatives: - Project Optimus: Evaluate early dose optimisation considering full impact of toxicity - Project FrontRunner: Develop and seek approval for advanced cancers in earlier clinical setting From drug-centered to patient-centred approaches to improve health outcomes and expand treatment access to all. See below for full article (p.60-64).

ASCO 2024 has revealed a game-changing shift in oncology treatments. Traditional aggressive treatments are being challenged by new evidence favoring less invasive approaches, promising better patient outcomes and quality of life. How will this impact your communication strategies? Commetric's latest ASCO 2024 Media Insights Report uncovers the new narrative of "doing less to achieve more" in cancer care. Discover key media trends and the most influential companies that are shaping this transformation. Follow the link in the comments below to download the report 👇 American Society of Clinical Oncology (ASCO), GSK, Takeda, Mainz Biomed, AstraZeneca, Medicenna Therapeutics Corp., Merck, Pfizer #oncology #pharma #healthcarePR

With oncology trial starts at historically high levels in 2022, the volume of innovation we’re seeing in cancer care is inspiring excitement in experts across the globe. In this article for European Biopharmaceutical Review, IQVIA’s Sari Heitner Enschede, Jose Luis Fernández García, and Matt Simmons take a deep-dive into the implications of oncology practice-shifting advancements on patient care. Read now. Pages 60-63 https://bit.ly/3TgpdI4 #oncology #clinicaltrials

Struggling to navigate FDA's Project FrontRunner for oncology drug development? Learn how to align your strategies with Project FrontRunner and accelerate the approval process ⏩ Our experts provide valuable insights to help you overcome the complexities and make informed decisions. 💻Watch our webinar now and gain a competitive edge in the evolving landscape of oncology drug development 📩 https://bit.ly/3w3xyGL #FDA #ProjectFrontRunner #Oncology